Survodutide
Also known as: BI 456906
By GLPeptideSciences Editorial Team · How we evaluate evidence · Reviewed by Dr. George S. Watson, MD, Cardiothoracic Surgeon · Updated 2026-06-02
An investigational dual GLP-1 and glucagon receptor agonist studied for obesity and metabolic liver disease (MASH/NASH).
What it is & how it works
What it is
Survodutide is an investigational dual agonist of the GLP-1 and glucagon receptors, developed for obesity and increasingly studied in metabolic liver disease.
How it is thought to work
The GLP-1 arm drives appetite and glucose effects; the glucagon arm is hypothesized to increase energy expenditure and influence liver fat — the basis for its MASH program.
The evidence and the caveat
Human data is building, including in liver disease, but it is incomplete and the compound is not approved. Non-trial product is unapproved and unverified.
What it's discussed & studied for
- Obesity / weight management (investigational)
- Metabolic liver disease / MASH (under study)
Discussion of a use is not a claim that it works or is approved.
Research status
Investigational; human trials ongoing across obesity and liver-disease programs. Not approved.
Evidence quality
Human trial data is accumulating, including in liver disease, but is incomplete and the compound is not approved.
Dosing discussion
Defined only within clinical trials; no approved label.
Educational summary of what is discussed in the literature and community — not a dosing recommendation or medical advice.
Safety & harm reduction
Gastrointestinal effects are common in trials. The glucagon-receptor component means the full profile is still being studied. Not approved.
Sourcing literacy
No approved product exists; research-market versions are unapproved and unverified.
Selected literature
FAQ
What makes survodutide notable?
Its dual GLP-1/glucagon action is being studied not only for weight but for metabolic liver disease (MASH), an area of high unmet need.
Is it approved?
No. It is investigational and in ongoing trials.